Daiichi Sankyo Company, Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DSNKY Over the counter 2830 www.daiichisankyo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daiichi Sankyo Company, Limited

Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer - Jul 17th, 2025 9:11 am
ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Jul 17th, 2025 6:00 am
Vynca Appoints Sandra Clarke to Board of Directors, Strengthening Commitment to Transformative Palliative Care - Jul 15th, 2025 6:00 am
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial - Jul 9th, 2025 6:00 am
AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer - Jun 28th, 2025 3:41 am
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE? - Jun 26th, 2025 7:47 am
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer - Jun 25th, 2025 4:30 am
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Jun 24th, 2025 7:04 am
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC - Jun 24th, 2025 3:39 am
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Jun 23rd, 2025 3:05 pm
MSD and Daiichi announce first subject dosing in prostate cancer trial - Jun 19th, 2025 3:31 am
Celltrion opens new UK headquarters in Uxbridge, UK - Jun 18th, 2025 8:49 pm
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer - Jun 18th, 2025 5:00 am
VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML - Jun 16th, 2025 6:00 am
Can Blue Origin Fill NASA’s SpaceX Void? - Jun 16th, 2025 4:30 am
Can Elon Musk’s Pajama Party Brighten Up Tesla’s Tomorrow? - Jun 15th, 2025 7:30 am
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Jun 10th, 2025 3:47 am
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Jun 9th, 2025 6:00 am
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - Jun 4th, 2025 10:03 am
DSNKY vs. ZTS: Which Stock Is the Better Value Option? - Jun 4th, 2025 9:40 am